Treatment Information

Back

Melanoma treatment details. Immunotherapy.

St. Luke's Medical Center, Bethlehem, PA, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:Bethlehem, PA
Treatments:ImmunotherapyHospital:St. Luke's Medical Center
Drugs:Journal:Link
Date:Sep 2007

Description:

Patients: This phase II trial involved twenty-six patients with metastatic melanoma. There were 12 men and 14 women. The median age was 45 years, ranging from 28-70. The patients’ disease had progressed during or after they were treated with biochemotherapy: cisplatin, vinblastine, dacarbazine, interleukin-2 and interferon alfa-2b.

Treatment: Patients were treated with an infusion of high-dose bolus interleukin-2.

Toxicity: Grade 3 and 4 toxicities included anemia, leukopenia, thrombocytopenia, tachycardia, hypotension, nausea, vomiting, diarrhea, renal and hepatic abnormalities (oliguria and increased bilirubin), infection, rash, and fatigue/delirium. Each of these occurred in less than 10 patients, except for hepatic (liver) abnormality, which occurred in 13 patients.

Results: The median overall survival was 9.6 months (41.9 weeks). The median progression-free survival was 10 weeks.

Correspondence: Dr. Sanjiv S. Agarwala



Back